SCHEMBL2363233

SCHEMBL2363233

COC(=O)CN(C1CCCCC1)[C@H]1CCN(C(=O)OCc2ccccc2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.51
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
PDE4B Q07343 2/20 0.48
CYP2C19 P33261 1/20 0.47
GRIN2B Q13224 4/20 0.44
USP30 Q70CQ3 1/20 0.44
CYP2D6 P10635 3/20 0.43
CYP2C9 P11712 3/20 0.43
PGR P06401 1/20 0.42
FKBP1A P62942 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
JAK2 O60674 1/20 0.42
JAK1 P23458 1/20 0.42
XIAP P98170 1/20 0.42
BIRC2 Q13490 1/20 0.42
MMP1 P03956 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5438425 0.89 SMN1; SMN2 (0.53) HTTSMN1; SMN2NPC1RAB9APDE4B
SCHEMBL8171722 0.83 HTT (0.55) HTTSMN1; SMN2NPC1RAB9APDE4B
SCHEMBL8044664 0.83 HTT (0.55) HTTSMN1; SMN2NPC1RAB9APDE4B
SCHEMBL2278719 0.79 SMN1; SMN2 (0.51) HTTSMN1; SMN2NPC1RAB9APDE4B
SCHEMBL24359316 0.79 SMN1; SMN2 (0.61) HTTSMN1; SMN2NPC1RAB9APDE4B
SCHEMBL21016652 0.79 SMN1; SMN2 (0.61) HTTSMN1; SMN2NPC1RAB9APDE4B
SCHEMBL3436803 0.79 SMN1; SMN2 (0.61) HTTSMN1; SMN2NPC1RAB9APDE4B
SCHEMBL21312056 0.77 SMN1; SMN2 (0.55) HTTSMN1; SMN2NPC1RAB9APDE4B
SCHEMBL21311670 0.77 SMN1; SMN2 (0.55) HTTSMN1; SMN2NPC1RAB9APDE4B
SCHEMBL3563739 0.77 SMN1; SMN2 (0.59) HTTSMN1; SMN2NPC1RAB9APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989634-B2 Melanocortin receptor agonists LG LIFE SCIENCES LTD. (KR) 2011-08-02 US disclosed
EP-1685102-A4 MELANOCORTIN RECEPTOR AGONISTS LG LIFE SCIENCES LTD (KR) 2008-08-20 EP disclosed
US-20070129346-A1 Melanocortin receptor agonists LG LIFE SCIENCES LTD. (KR) 2007-06-07 US disclosed
EP-1685102-A1 MELANOCORTIN RECEPTOR AGONISTS LG Life Sciences Ltd. (KR) 2006-08-02 EP disclosed
WO-2005047251-A1 MELANOCORTIN RECEPTOR AGONISTS LG LIFE SCIENCES LTD. (KR) 2005-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129346-A1 Melanocortin receptor agonists MC1R, MC3R, MC5R HTT 1199/4885SMN1; SMN2 2404/4885NPC1 1600/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.